These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 12743496

  • 1. [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].
    Guyétant S, Michalak S, Valo I, Saint-André JP.
    Ann Pathol; 2003 Feb; 23(1):11-20. PubMed ID: 12743496
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL.
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
    Bogdańska M, Górnicka B, Ziarkiewicz-Wróblewska B, Koperski L, Morton M, Wasiutyński A.
    Endokrynol Pol; 2006 Apr; 57(4):314-9. PubMed ID: 17006830
    [Abstract] [Full Text] [Related]

  • 4. [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
    Laco J, Ryska A.
    Cesk Patol; 2006 Jul; 42(3):120-4. PubMed ID: 16955558
    [Abstract] [Full Text] [Related]

  • 5. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma.
    Vasko VV, Gaudart J, Allasia C, Savchenko V, Di Cristofaro J, Saji M, Ringel MD, De Micco C.
    Eur J Endocrinol; 2004 Dec; 151(6):779-86. PubMed ID: 15588246
    [Abstract] [Full Text] [Related]

  • 6. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
    Raphael SJ, McKeown-Eyssen G, Asa SL.
    Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
    [Abstract] [Full Text] [Related]

  • 7. Interpretation of RET immunostaining in follicular lesions of the thyroid.
    Cerilli LA, Mills SE, Rumpel CA, Dudley TH, Moskaluk CA.
    Am J Clin Pathol; 2002 Aug; 118(2):186-93. PubMed ID: 12162676
    [Abstract] [Full Text] [Related]

  • 8. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
    Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S.
    APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
    Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV.
    Endocr Pathol; 2006 May; 17(3):213-23. PubMed ID: 17308358
    [Abstract] [Full Text] [Related]

  • 10. Follicular, papillary, and "hybrid" carcinomas of the thyroid.
    Castro P, Fonseca E, Magalhães J, Sobrinho-Simões M.
    Endocr Pathol; 2002 May; 13(4):313-20. PubMed ID: 12665649
    [Abstract] [Full Text] [Related]

  • 11. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
    Park KY, Koh JM, Kim YI, Park HJ, Gong G, Hong SJ, Ahn IM.
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
    [Abstract] [Full Text] [Related]

  • 12. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
    Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F.
    J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
    [Abstract] [Full Text] [Related]

  • 13. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
    Mai KT, Bokhary R, Yazdi HM, Thomas J, Commons AS.
    Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
    [Abstract] [Full Text] [Related]

  • 14. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
    Schröder S, Wodzynski A, Padberg B.
    Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
    [Abstract] [Full Text] [Related]

  • 15. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD, Wang LJ, Yao HT, Li J, Ding W, Yan LP.
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [Abstract] [Full Text] [Related]

  • 16. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
    Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A.
    Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
    [Abstract] [Full Text] [Related]

  • 17. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
    Mai KT, Landry DC, Thomas J, Burns BF, Commons AS, Yazdi HM, Odell PF.
    Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G.
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [Abstract] [Full Text] [Related]

  • 19. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
    He CN, He L, Cheng JQ, Chen SC, Zhao HF, Zhai JP, Zhang J.
    Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
    [Abstract] [Full Text] [Related]

  • 20. Papillary carcinoma of the thyroid: a tumour still with no benign neoplastic counterpart.
    Stephenson TJ.
    Histopathology; 2001 Nov; 39(5):536-8. PubMed ID: 11737313
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.